This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the gastric cancer (GC) market, including: initiation of BeiGene's two Phase III trials with tislelizumab (BGB-A317) in locally advanced unresectable or metastatic gastric or gastro-oesophageal junction (GEJ) adenocarcinoma, and unresectable, locally advanced recurrent or metastatic oesophageal squamous cell carcinoma (ESCC); initiation of Deciphera Pharmaceuticals' second Phase III study with ripretinib (DCC-2618), which is being compared against sunitinib (Sutent; Pfizer) in the second-line treatment of gastrointestinal stromal tumours (GIST); and US Food and Drug Administration approval of Taiho Oncology's Lonsurf (trifluridine + tipiracil) in patients with metastatic gastric or GEJ adenocarcinoma previously treated with at least two prior lines of chemotherapy.
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved